Real-World Treatment Patterns and Sequencing of ALK-Inhibitors in ALK-Positive NSCLC Treated with Palliative Intent
Background: ALK-rearranged non-small cell lung cancer (NSCLC) is a molecularly defined subtype that is highly sensitive to ALK tyrosine kinase inhibitors (ALK inhibitors). With multiple generations of ALK inhibitors available, real-world data on treatment patterns and sequencing in routine clinical practice remain limi...